Recently, Palmieri et al from Italy published an interesting finding. In this spontaneous spontaneous anecdotal, retrospective, “compassionate-use,” observational, open-label study, 12 females (age 12–24 years) with severe somatoform and dysautonomic syndrome following HPV vaccination were given sublingual CBD-rich hemp oil drops, 25 mg/kg per day supplemented by 2–5 mg/ml CBD once a week until a maximum dose of 150 mg/ml CBD per day was reached over a 3 month period. Patients’ quality of life was evaluated using the medical
outcome short-form health survey questionnaire (SF-36).
In the study, two patients were excluded from the study after the first month of treatment due to complaints of mild side effects: hyperglycemia in one patient with diabetes mellitus, and moderate sleepiness and confusion in the second patient. Another two patients decided to withdraw early as they experienced no benefit from the trial. SF-36 revealed significant improvements in the physical component score (P < 0.02), vitality (P < 0.03) and social role functioning (P < 0.02) after treatment. The administration of hemp oil also significantly reduced body pain assessed by the SF-36. No significant differences in role limitations due to emotional functioning (P= 0.02) for the period before treatment until 3 months posttreatment were found.
Cannabis sativa plant derivatives have long been used in folk medicine as symptomatic treatment for many disorders, including anorexia and pain . Cannabis contains more than 80 phytocannabinoids, but little is known about the potential therapeutic effects of most of these molecules. The major neuroactive components are Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD). Δ9-THC activates the endocannabinoid system, a widespread network of G protein-coupled cannabinoid (CB) receptors, synthetic and degradative enzymes, and transporters including anandamide and 2-arachidonoylglycerol, CB1 and CB2 endogenous ligands. In the central nervous system, Δ9-THC influences synaptic communication and modulates eating, anxiety, learning and memory, growth and development. To exert its effects this compound binds to two G protein-coupled cell membrane receptors – cannabinoid type 1 (CB1) and type 2 (CB2) receptors that are found primarily in the brain and in immune and hematopoietic cells, respectively. The potential medical use of whole-plant cannabis extracts is limited by the psychoactive properties and the adverse effects associated with long-term Δ9-THC use.
CBD displays a broad spectrum of pharmacological effects with multiple potential sites of action in the gastrointestinal, nervous, muscular, and immune systems; these include antiinflammatory and anti-nociceptive effects, as well as neuroprotective activity. As a pure nutraceutical compound, the CBD enriched hemp oil in our preliminary ongoing wide-range pilot study is a promising effective strategy for the treatment of several diseases, including neuropathic pain, fibromyalgia, macrophagic myofasciitis, herpetic neuralgia, etc. Further formal case-control blind clinical investigations are urgently required to introduce regular use of CBD-enriched hemp oil and assess its impact on ADRs subsequent to HPV vaccine, taking into account the general safety and good compliance of long-term administration. In the authors Second Opinion Medical Network, they were not able to find any better effective symptomatic treatment and thus we emphasize the advantage of cannabinoid sublingual oil administration for this puzzling orphan disease with a severely compromised quality of life, as well as school difficulties
and social impairment